Preferred Label : Leronlimab;
NCIt definition : A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor
5 (CCR5; CD195), with potential activity as a human immunodeficiency virus (HIV) entry
blocker and potential protective activity against graft-versus-host disease (GvHD).
Upon administration, leronlimab targets and binds to CCR5 expressed on T-cells. This
blocks HIV cell entry, which prevents HIV infection and/or reduces HIV viral load.
In addition, blocking CCR5 by PRO 140 decreases CCR5-mediated signaling and the CCR5-induced
migration of donor cells into tissues after an allogeneic hematopoietic cell transplantation
(HCT). Blocking CCR5 may therefore prevent or reduce GvHD. CCR5, a co-receptor needed
for HIV cell entry, plays a key role in immunomodulation. Expressed on monocytes,
activated T-cells and dendritic cells (DCs), CCR5 can regulate chemotaxis. Lymphocyte
trafficking via chemokine receptors, such as CCR5, and recruitment to target organs,
plays a critical role in alloreactive responses.;
UNII : Y1J4NP8FF0;
CAS number : 674782-26-4;
Molecule name : PRO 140; PA14; WHO 10751; PRO-140;
Origin ID : C137824;
UMLS CUI : C4730999;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
